Insider · SEC Form 4 filer

Mark Lappe

Companies

Where they file as an insider

Inhibrx Biosciences (INBX) CEO, Director Latest filing Oct 14, 2026
Inhibrx (INBX) CEO, Director Latest filing May 30, 2024

Track record

Did their buys beat the typical stock?

Open-market buys27
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check2

Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.

Inhibrx Biosciences (INBX) Bought Oct 14, 2026 · $849K · 10,040 shares Too new Too new. Its 6-month check uses prices as of Jun 30, 2027.
Inhibrx Biosciences (INBX) Bought Sep 8–28, 2026 · $3.64M · 35,000 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Inhibrx Biosciences (INBX) Bought Aug 20–Sep 16, 2024 · $2.42M · 164,000 shares Behind typical Sep 30, 2024 $15.66 → Mar 31, 2025 $13.99 · −10.7% (typical stock −7.5%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist